Recent Updates
Recently added Catalysts

Relapsed and Refractory Multiple Myeloma: one US-listed biotech with a clinical-stage programme

OncologyUncontestedData as of 2026-09-04

Competitors1in the clinic
Median market cap$156Muniverse median $1.20B
Allocated capital$156M$156M competing
Phase 3 or filed00 mid, 1 early
Pure plays1this indication only
Capital rank266/299crowding rank 268

Relapsed and Refractory Multiple Myeloma is uncontested. Caribou Biosciences (CRBU) is the only US-listed developer in the $100M to $20B band running a clinical programme here, with CB-011 in phase 1.

There is no public comparable to price it against, and CRBU runs clinical programmes in this indication and nothing else, so its $156M market cap is a direct read on what the market thinks this programme is worth.

Nothing here has reached Phase 3: 0 programmes in mid stage and 1 in early stage, so the field is still several years from a first approval.

$156M of allocated capital sits in Relapsed and Refractory Multiple Myeloma, ranking it 266th of 299 indications by the money committed to it.

Companies developing drugs for Relapsed and Refractory Multiple Myeloma 1

TickerCompanyLead assetPhaseTrialsMarket capPure playIndicationsNext catalyst
CRBUCaribou BiosciencesCB-011Phase 11$156MYes1 31 Dec 2026

Sorted by phase, then by market capitalisation. Ticker links open the company profile.

Why Relapsed and Refractory Multiple Myeloma counts as uncontested

Uncontested. One US-listed developer in the size band is running a clinical programme here, so there is no public comparable to price it against.

The map splits indications on two folds: six or more competitors counts as crowded, and a median company above $1.20B counts as richly priced. Relapsed and Refractory Multiple Myeloma has one competitor and a median of $156M.

Oncology

Oncology holds $187B of the map's capital, 27.8% of the total, spread across 119 indications and 103 companies. 34 of those indications have more than one company competing.

See every Oncology indication on the map

Related indications in Oncology

Metastatic Lung Cancer1 company · $162M · median $486MUncontestedT-Cell Lymphoblastic Leukemia/Lymphoma2 companies · $149M · median $374MOrphan cornerAdvanced Hepatocellular Carcinoma1 company · $175M · median $175MUncontestedLeukemia1 company · $176M · median $176MUncontestedStage IV Merkel Cell Carcinoma1 company · $134M · median $134MUncontestedChronic Myeloid Leukemia1 company · $180M · median $1.6BUncontestedPhiladelphia Chromosome Positive Acute Lymphocytic Leukemia1 company · $180M · median $1.6BUncontestedLiposarcoma1 company · $180M · median $1.6BUncontested

Relapsed and Refractory Multiple Myeloma pipeline questions

Which biotech companies are developing drugs for Relapsed and Refractory Multiple Myeloma?

Caribou Biosciences (CRBU, CB-011, Phase 1). Those are the 1 US-listed developer in the $100M to $20B market cap band with a clinical-stage programme in Relapsed and Refractory Multiple Myeloma.

How advanced is the Relapsed and Refractory Multiple Myeloma pipeline?

Of the 1 clinical-stage programme in Relapsed and Refractory Multiple Myeloma, 0 are in Phase 3 or filed, 0 are in mid-stage development and 1 is in early-stage development.

Is anyone else developing a drug for Relapsed and Refractory Multiple Myeloma?

No. CRBU is the only US-listed company in the $100M to $20B market cap band with a clinical-stage programme in Relapsed and Refractory Multiple Myeloma, which is why the indication is classified as uncontested.

When is the next Relapsed and Refractory Multiple Myeloma catalyst?

The next dated catalyst in Relapsed and Refractory Multiple Myeloma is CRBU on 31 Dec 2026. 1 dated event across the field fall in the next 12 months.

How this page is built

  • Universe is US-listed drug developers with a $100M to $20B market capitalisation, identified by SEC SIC code 2833, 2834 or 2836 or by a pharmaceutical or biotechnology industry classification, less a reviewed exclusion list of contract research organisations, device and diagnostics makers and diversified generics manufacturers.
  • An asset attributed to three or more different companies is treated as shared standard of care rather than any one company’s programme and excluded. Pembrolizumab alone appears under 21 tickers in raw trial data.
  • A programme counts only where at least one industry-sponsored trial supports it, so investigator-initiated academic studies of third-party drugs are excluded.

Allocated capital divides each company’s market capitalisation evenly across the indications it is running clinical programmes in, so every dollar of the universe is counted exactly once. Total market capitalisation competing counts a company in each of its indications and therefore sums to more than the universe.

Third-party market size estimates are not used anywhere on this page. Approved incumbents are excluded from competitor counts, and companies above $20B are outside the universe by construction.

Back to the disease map